360 Network | THE GUIDE | February 1, 2009

360 Network

Click here to view a 360 Guide from a past issue of Ophthalmology Times .

Related Videos
Related Content

Nacuity Pharmaceuticals achieves target enrollment for Phase 1/2 clinical trial of NPI-001 for treatment of retinitis pigmentosa associated with Usher syndrome

June 1st 2023

Podcast: Wet AMD and the treatment burden on patients

May 3rd 2023

Coave Therapeutics announces positive data from Phase I/II clinical trial of CTx-PDE6b

May 31st 2023

Podcast: AI/MR in ophthalmology: The future is now

April 7th 2023

New FDA blood donor recommendations could ease restrictions on cornea donations from gay, bisexual men

May 31st 2023

Preservative-free latanoprost vs BAK-preserved latanoprost

May 31st 2023

Nacuity Pharmaceuticals achieves target enrollment for Phase 1/2 clinical trial of NPI-001 for treatment of retinitis pigmentosa associated with Usher syndrome

June 1st 2023

Podcast: Wet AMD and the treatment burden on patients

May 3rd 2023

Coave Therapeutics announces positive data from Phase I/II clinical trial of CTx-PDE6b

May 31st 2023

Podcast: AI/MR in ophthalmology: The future is now

April 7th 2023

New FDA blood donor recommendations could ease restrictions on cornea donations from gay, bisexual men

May 31st 2023

Preservative-free latanoprost vs BAK-preserved latanoprost

May 31st 2023

Nacuity Pharmaceuticals achieves target enrollment for Phase 1/2 clinical trial of NPI-001 for treatment of retinitis pigmentosa associated with Usher syndrome

June 1st 2023

Podcast: Wet AMD and the treatment burden on patients

May 3rd 2023

Coave Therapeutics announces positive data from Phase I/II clinical trial of CTx-PDE6b

May 31st 2023

Podcast: AI/MR in ophthalmology: The future is now

April 7th 2023

New FDA blood donor recommendations could ease restrictions on cornea donations from gay, bisexual men

May 31st 2023

Preservative-free latanoprost vs BAK-preserved latanoprost

May 31st 2023
© 2023 MJH Life Sciences

All rights reserved.